A multiplex platform for the identification of ovarian cancer biomarkers.

ABSTRACT: BACKGROUND:Currently, there are no FDA approved screening tools for detecting early stage ovarian cancer in the general population. Development of a biomarker-based assay for early detection would significantly improve the survival of ovarian cancer patients. METHODS:We used a multiplex approach to identify protein biomarkers for detecting early stage ovarian cancer. This new technology (Proseek® Multiplex Oncology Plates) can simultaneously measure the expression of 92 proteins in serum based on a proximity extension assay. We analyzed serum samples from 81 women representing healthy, benign pathology, early, and advanced stage serous ovarian cancer patients. RESULTS:Principle component analysis and unsupervised hierarchical clustering separated patients into cancer versus non-cancer subg

SUBMITTER: Boylan KLM 

PROVIDER: S-EPMC5634875 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature